文献速递乳腺癌

紫杉醇联合卡铂辅助化疗对三阴性乳腺癌生存的影响:3期随机临床试验

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该3期随机试验纳入647例可手术三阴性乳腺癌患者,比较6周期紫杉醇+卡铂(PCb)与3周期CEF序贯3周期多西他赛(CEF-T)辅助化疗。结论提示PCb是可行替代方案。

要点

  • PCb方案较CEF-T显著改善可手术TNBC的5年无病生存(86.5% vs 80.3%)。
  • 总生存两组无统计学显著差异(HR=0.71,95%CI 0.42-1.22)。
  • HRR变异亚组PCb的DFS HR=0.39(95%CI 0.15-0.99),为探索性结果。

核心结论

  • 紫杉醇联合卡铂是可行三阴性乳腺癌的有效替代辅助化疗选择。
  • PCb对比CEF-T显著延长无病生存,但总生存无显著差异。

研究设计与样本

  • 在中国9个癌症中心开展的3期随机临床试验(NCT01216111)。
  • 2011年7月至2016年4月纳入647例18-70岁可手术TNBC女性,随机接受PCb(n=325)或CEF-T(n=322)。
  • 主要终点为无病生存,按意向治疗人群分析。

主要发现

  • 远处无病生存和無复发生存结果与DFS相似。
  • 安全性数据与相关药物已知安全性特征一致。

关键数值与推荐

  • PCb方案:紫杉醇80 mg/m2+卡铂AUC=2,第1、8、15天给药,每28天为一周期,共6周期。
  • CEF-T方案:环磷酰胺500 mg/m2+表柔比星100 mg/m2+氟尿嘧啶500 mg/m2,每3周一次,共3周期;序贯多西他赛100 mg/m2,每3周一次,共3周期。
  • 入组条件:可手术TNBC,病理确认区域淋巴结阳性或淋巴结阴性且肿瘤直径>10 mm。

临床怎么用

  • 对于可手术三阴性乳腺癌,PCb可作为辅助化疗的替代选择。
  • PCb方案在HRR变异亚组中显示潜在获益,但需进一步研究验证。
  • 临床决策时应结合患者分子分型及耐受性个体化选择方案。

局限性

  • BRCA1/2和HRR变异亚组分析为探索性、假设生成性,样本量有限。
  • 总生存数据尚未成熟,无显著差异。
  • 研究仅在中国人群中进行,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. OBJECTIVE: To compare 6 cycles of paclitaxel plus carboplatin (PCb) with a standard-dose regimen of 3 cycles of cyclophosphamide, epirubicin, and fluorouracil followed by 3 cycles of docetaxel (CEF-T). DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomized clinical trial was conducted at 9 cancer centers and hospitals in China. Between July 1, 2011, and April 30, 2016, women aged 18 to 70 years with operable TNBC after definitive surgery (having pathologically confirmed regional node-positive disease or node-negative disease with tumor diameter >10 mm) were screened and enrolled. Exclusion criteria included having metastatic or locally advanced disease, having non-TNBC, or receiving preoperative anticancer therapy. Data were analyzed from December 1, 2019, to January 31, 2020, from the intent-to-treat population as prespecified in the protocol. INTERVENTIONS: Participants were randomized to receive PCb (paclitaxel 80 mg/m2 and carboplatin [area under the curve = 2] on days 1, 8, and 15 every 28 days for 6 cycles) or CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles). MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival (DFS). Secondary end points included overall survival, distant DFS, relapse-free survival, DFS in patients with germline variants in BRCA1/2 or homologous recombination repair (HRR)-related genes, and toxicity. RESULTS: A total of 647 patients (mean [SD] age, 51 [44-57] years) with operable TNBC were randomized to receive CEF-T (n = 322) or PCb (n = 325). At a median follow-up of 62 months, DFS time was longer in those assigned to PCb compared with CEF-T (5-year DFS, 86.5% vs 80.3%, hazard ratio [HR] = 0.65; 95% CI, 0.44-0.96; P = .03). Similar outcomes were observed for distant DFS and relapse-free survival. There was no statistically significant difference in overall survival between the groups (HR = 0.71; 95% CI, 0.42-1.22, P = .22). In the exploratory and hypothesis-generating subgroup analyses of PCb vs CEF-T, the HR for DFS was 0.44 (95% CI, 0.15-1.31; P = .14) in patients with the BRCA1/2 variant and 0.39 (95% CI, 0.15-0.99; P = .04) in those with the HRR variant. Safety data were consistent with the known safety profiles of relevant drugs. CONCLUSIONS AND RELEVANCE: These findings suggest that a paclitaxel-plus-carboplatin regimen is an effective alternative adjuvant chemotherapy choice for patients with operable TNBC. In the era of molecular classification, subsets of TNBC sensitive to PCb should be further investigated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01216111.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yu KD, Ye FG, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32789480. doi:10.1001/jamaoncol.2020.2965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。